Statement: Cases of Cardiomyopathy and Coagulation disorders were only observed in cohort 1 of the primary trial.
Primary_evidence: Adverse Events 1:   Total: 331/1634 (20.26%)   Anemia 3/1634 (0.18%)   Coagulation disorders 1/1634 (0.06%)   Hemorrhage Vaginal 1/1634 (0.06%)   Leukopenia 18/1634 (1.10%)   Lymphadenopathy 0/1634 (0.00%)   Lymphedema 0/1634 (0.00%)   Pancytopenia 0/1634 (0.00%)   Thrombocytopenia 0/1634 (0.00%)   Arrhythmia 3/1634 (0.18%)   Arrhythmia Ventricular 0/1634 (0.00%)   Cardiomyopathy 1/1634 (0.06%) Adverse Events 2:   Total: 520/1635 (31.80%)   Anemia 5/1635 (0.31%)   Coagulation disorders 0/1635 (0.00%)   Hemorrhage Vaginal 0/1635 (0.00%)   Leukopenia 56/1635 (3.43%)   Lymphadenopathy 1/1635 (0.06%)   Lymphedema 2/1635 (0.12%)   Pancytopenia 1/1635 (0.06%)   Thrombocytopenia 1/1635 (0.06%)   Arrhythmia 3/1635 (0.18%)   Arrhythmia Ventricular 1/1635 (0.06%)   Cardiomyopathy 0/1635 (0.00%)